Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Summary Background Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2014-09, Vol.15 (10), p.1090-1099
Hauptverfasser:	Burger, Jan A, Dr, Keating, Michael J, Prof, Wierda, William G, Prof, Hartmann, Elena, MD, Hoellenriegel, Julia, MS, Rosin, Nathalie Y, PhD, de Weerdt, Iris, MD, Jeyakumar, Ghayathri, MD, Ferrajoli, Alessandra, MD, Cardenas-Turanzas, Marylou, PhD, Lerner, Susan, MS, Jorgensen, Jeffrey L, MD, Nogueras-González, Graciela M, MS, Zacharian, Gracy, MS, Huang, Xuelin, PhD, Kantarjian, Hagop, Prof, Garg, Naveen, MD, Rosenwald, Andreas, Prof, O'Brien, Susan, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived - adverse effects Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cell adhesion & migration Constipation Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Drug therapy Female Hematology, Oncology and Palliative Medicine Humans Infections Insomnia Kaplan-Meier Estimate Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Maximum Tolerated Dose Medical prognosis Middle Aged Mutation Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Patient Selection Prognosis Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Quality of life Rituximab Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Background Ibrutinib, an orally administered covalent inhibitor of Bruton's tyrosine kinase (BTK), is an effective treatment for relapsed chronic lymphocytic leukaemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab in patients with high-risk CLL. Methods In this single-arm phase 2 study, we enrolled adult patients with high-risk CLL at the MD Anderson Cancer Center (Houston, TX, USA). All enrolled participants had high-risk cytogenetic abnormalities (deletion 17p, TP53 mutation, or deletion 11q) or a short progression-free survival (PFS
ISSN:	1470-2045 1474-5488
DOI:	10.1016/S1470-2045(14)70335-3